Manufacturer 340B Restrictions for Oregon
- Details
- Published: Tuesday, 14 October 2025 08:37
- Written by 340B Editor
Oregon House Bill 2385 prohibits drug manufacturers from interfering—directly or indirectly—with pharmacies or drug outlets that acquire, deliver, or dispense 340B drugs to eligible healthcare providers. It also bans manufacturers from requiring utilization review data as a condition for accessing 340B drugs.
Below is the current status of manufacturer restrictions for Oregon.
|
Manufacturer Name |
Specific Drugs |
Current CP Policy - CE Applicability |
CP Policy Original Effective Date |
CP Policy Original Notice Date |
CP Policy - Date first applied to FQHC's |
OR Exemption Announcement date |
OREGON Exempted Date |
Single CP Designation Allowed? |
CP Rx Data Submission Req to 340BESP? |
|
Biogen |
All |
OR Exempted |
2/1/2023 |
12/1/2022 |
12/19/24 |
9/22/25 |
9/26/25 |
Yes |
Yes |
|
Boehringer Ingelheim |
All |
OR Exempted |
8/1/2021 |
6/30/2021 |
9/1/22 |
8/19/25 |
9/26/25 |
Yes |
Yes |
|
Liquidia |
All |
OR Exempted |
3/1/2024 |
3/1/2024 |
3/1/24 |
9/24/25 |
9/26/25 |
Yes |
Yes |
|
Merck |
All |
OR Exempted |
9/1/2021 |
8/1/2021 |
5/31/22 |
9/22/25 |
9/26/25 |
Yes |
Yes |
|
Organon |
All |
OR Exempted |
7/1/2023 |
6/1/2023 |
7/1/23 |
10/7/25 |
9/29/25 |
Yes |
Yes |
|
Alkermes |
All |
OR Exempted |
7/22/2024 |
6/4/2024 |
7/22/24 |
8/22/25 |
9/1/25 |
Yes |
No |
|
GlaxoSmithKline |
All |
OR Exempted |
4/1/2022 |
2/1/2022 |
5/1/23 |
9/12/25 |
9/28/25 |
Yes |
No |
|
GlaxoSmithKline |
GSK - Benlysta |
OR Exempted |
4/1/2022 |
2/1/2022 |
5/1/23 |
9/12/25 |
9/28/25 |
Yes |
No |
|
GlaxoSmithKline |
GSK - Flolan |
OR Exempted |
4/1/2022 |
2/1/2022 |
5/1/23 |
9/12/25 |
9/28/25 |
Yes |
No |
|
GlaxoSmithKline |
GSK - Nucala |
OR Exempted |
4/1/2022 |
2/1/2022 |
5/1/23 |
9/12/25 |
9/28/25 |
Yes |
No |
|
GlaxoSmithKline |
GSK - Ojjaara |
OR Exempted |
4/1/2022 |
2/1/2022 |
5/1/23 |
9/12/25 |
9/28/25 |
Yes |
No |
|
GlaxoSmithKline |
GSK - Zejula |
OR Exempted |
4/1/2022 |
2/1/2022 |
5/1/23 |
9/12/25 |
9/28/25 |
Yes |
No |
|
Sobi |
All |
OR Exempted |
7/1/2024 |
6/3/2024 |
6/3/2024 |
9/24/25 |
9/26/25 |
Yes |
No |
|
UCB |
All |
OR Exempted |
12/13/2021 |
11/1/2021 |
10/24/24 |
10/13/25 |
10/13/25 |
Yes |
No |
|
Teva |
All |
OR Exempted |
7/5/2023 |
6/8/2023 |
n/a |
9/24/25 |
9/28/25 |
N/A |
N/A |
|
Abbvie |
All |
FQHC |
2/1/2022 |
12/1/2021 |
? |
Yes |
Yes |
||
|
AstraZeneca |
All |
FQHC |
10/1/2020 |
8/17/2020 |
10/1/20 |
Yes |
Yes |
||
|
Bayer |
All |
FQHC |
3/1/2023 |
2/1/2023 |
6/24/24 |
Yes |
Yes |
||
|
Bristol Myers Squibb |
All |
FQHC |
3/1/2022 |
1/14/2022 |
7/1/24 |
Yes |
Yes |
||
|
Bristol Myers Squibb |
Bristol Myers Squibb - LMiD |
FQHC |
3/1/2022 |
1/14/2022 |
7/1/24 |
Yes |
Yes |
||
|
Bristol Myers Squibb |
Bristol Myers Squibb - Camzyos |
FQHC |
3/1/2022 |
1/14/2022 |
7/1/24 |
Yes |
Yes |
||
|
Bristol Myers Squibb |
Bristol Myers Squibb - Krazati |
FQHC |
3/1/2022 |
1/14/2022 |
7/1/24 |
Yes |
Yes |
||
|
Eli Lilly |
All |
FQHC |
7/1/2020 |
6/1/2020 |
7/1/20 |
Yes |
Yes |
||
|
Exelixis |
All |
FQHC |
7/6/2022 |
6/1/2022 |
7/6/22 |
Yes |
Yes |
||
|
Gilead |
All |
FQHC |
5/2/2022 |
3/1/2022 |
5/2/22 |
Yes |
Yes |
||
|
Mitsubishi Tanabe Pharma America |
All |
FQHC |
10/1/2025 |
9/2/2025 |
10/2/25 |
Yes |
Yes |
||
|
Novo Nordisk |
All |
FQHC |
1/1/2021 |
12/1/2020 |
7/1/24 |
Yes |
Yes |
||
|
United Therapeutics |
All |
FQHC |
11/20/2020 |
11/18/2020 |
11/20/20 |
Yes |
Yes |
||
|
Amgen |
All |
FQHC |
1/3/2022 |
12/21/2021 |
3/19/24 |
Yes |
No |
||
|
Bausch + Lomb* |
All |
FQHC |
7/1/2024 |
6/5/2024 |
7/1/24 |
Yes |
No |
||
|
Bausch Health* |
All |
FQHC |
4/1/2020 |
4/1/2020 |
4/1/20 |
Yes |
No |
||
|
EMD SERONO INC |
All |
FQHC |
3/1/2023 |
2/1/2023 |
3/1/2023 |
Yes |
No |
||
|
Novartis |
All |
FQHC |
10/1/2020 |
8/17/2020 |
? |
Yes |
No |
||
|
Sumitomo |
All |
FQHC |
5/1/2024 |
4/1/2024 |
5/1/2024 |
Yes |
No |
||
|
Sumitomo |
Sumitomo - Orgovyx |
FQHC |
5/1/2024 |
4/1/2024 |
5/1/2024 |
Yes |
No |
||
|
Viatris |
All |
FQHC |
8/1/2024 |
7/1/2024 |
8/1/2024 |
Yes |
No |
||
|
Sanofi |
All |
FQHC |
10/1/2020 |
8/1/2020 |
10/1/20 |
No |
No |
*Manufacturer Withdrawn From 340B Program.
Graph courtesy of Marcus Cox, RPh, Chief Pharmacy Officer, Klamath Health Partnership, Inc, Oregon